NCT00548899 - Neoadjuvant Chemotherapy Including Sorafenib in Women With Previously Untreated Primary Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

September 30, 2011

Study Completion Date

December 31, 2011

Conditions

Breast Cancer

Interventions

DRUG

Nexavar (Sorafenib)

Tablet, Sorafenib follows a patient specific escalation scheme starting with 200 mg daily up to a maximum dose of 800 mg daily during EC chemotherapy on day 2-19. The achieved dose will be continued during paclitaxel chemotherapy during week 1-11 all day

Trial Locations (9)

10713

St. Gertrauden Krankenhaus, Berlin

18059

Klinikum Südstadt, Rostock

24105

Universitätsklinikum Schleswig-Holstein Campus Kiel, Kiel

30559

Henriettenstiftung, Hanover

34177

Elisabeth Krankenhaus, Kassel

50924

Klinikum der Universität zu Köln, Cologne

60590

Klinikum der J. W. Goethe Universität, Frankfurt am Main

63069

Klinikum Offenbach, Offenbach

65199

Dr.-Horst-Schmidt-Kliniken GmbH, Wiesbaden